NO20065676L - Forebyggelse av arteriell restenose med aktive vitamin D forbindelser. - Google Patents

Forebyggelse av arteriell restenose med aktive vitamin D forbindelser.

Info

Publication number
NO20065676L
NO20065676L NO20065676A NO20065676A NO20065676L NO 20065676 L NO20065676 L NO 20065676L NO 20065676 A NO20065676 A NO 20065676A NO 20065676 A NO20065676 A NO 20065676A NO 20065676 L NO20065676 L NO 20065676L
Authority
NO
Norway
Prior art keywords
animal
prevention
compounds
active vitamin
arterial restenosis
Prior art date
Application number
NO20065676A
Other languages
English (en)
Norwegian (no)
Inventor
Martha J Whitehouse
Bradford Goodwin
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of NO20065676L publication Critical patent/NO20065676L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20065676A 2004-05-10 2006-12-08 Forebyggelse av arteriell restenose med aktive vitamin D forbindelser. NO20065676L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56924104P 2004-05-10 2004-05-10
PCT/US2005/016282 WO2005110435A1 (en) 2004-05-10 2005-05-10 Prevention of arterial restenosis with active vitamin d compounds

Publications (1)

Publication Number Publication Date
NO20065676L true NO20065676L (no) 2007-01-31

Family

ID=35393991

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065676A NO20065676L (no) 2004-05-10 2006-12-08 Forebyggelse av arteriell restenose med aktive vitamin D forbindelser.

Country Status (10)

Country Link
US (2) US20070142339A1 (es)
EP (1) EP1750728A4 (es)
JP (1) JP2007537263A (es)
KR (1) KR20070038460A (es)
CN (1) CN1950095A (es)
AU (1) AU2005244061A1 (es)
CA (1) CA2566346A1 (es)
MX (1) MXPA06013029A (es)
NO (1) NO20065676L (es)
WO (1) WO2005110435A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
JP2007501864A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 活性ビタミンｄ化合物単独または他の治療薬との併用による、免疫介在疾患の治療法
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2004110151A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
US20070142339A1 (en) * 2004-05-10 2007-06-21 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
US20070275934A1 (en) * 2004-05-10 2007-11-29 Curd John G Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
WO2006060765A2 (en) * 2004-12-02 2006-06-08 Abbott Laboratories Use of a compound that activates a vitamin d receptor for reducing intimal hyperplasia, smooth muscle cell proliferation and restenosis in mammals
WO2006074226A2 (en) * 2005-01-05 2006-07-13 Novacea, Inc. Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
WO2007038428A2 (en) * 2005-09-26 2007-04-05 Novacea, Inc. Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US7286295B1 (en) 2005-11-30 2007-10-23 Sandia Corporation Microoptical compound lens
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
JP2010511427A (ja) * 2006-12-01 2010-04-15 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ コラーゲン阻害剤を含む医療デバイス
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
US10098897B2 (en) * 2014-07-17 2018-10-16 Mayo Foundation For Medical Education And Research Methods and materials for reducing development of stenosis of arteriovenous fistulas
KR20240045379A (ko) 2014-12-05 2024-04-05 알렉시온 파마슈티칼스, 인코포레이티드 재조합 알칼리성 포스파타제를 이용한 발작 치료
EP3250227A2 (en) 2015-01-28 2017-12-06 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
CN108431019A (zh) 2015-10-07 2018-08-21 阿佩利斯制药有限公司 给药方案
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
CN109152820A (zh) 2016-04-01 2019-01-04 阿雷克森制药公司 用碱性磷酸酶治疗肌肉无力
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS FOR TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
MX2019012033A (es) 2017-04-07 2019-12-05 Apellis Pharmaceuticals Inc Regímenes de dosificación y composiciones y métodos relacionados.
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US6902911B1 (en) * 1997-11-19 2005-06-07 Zymogenetics, Inc. Human 2-19 protein homologue z219C
AU762481C (en) * 1998-03-27 2004-08-19 Oregon Health Sciences University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
EP1270026A1 (en) * 2001-06-22 2003-01-02 Erik Andersen Stents comprising vitamin D analogues for restenosis inhibition
PT1436257E (pt) * 2001-10-12 2007-05-31 Cytochroma Inc Análogos oxima de calcemia baixa de 1-alfa, 25-di-hidroxivitamina d3
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
JP2007501864A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 活性ビタミンｄ化合物単独または他の治療薬との併用による、免疫介在疾患の治療法
WO2004110151A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
WO2005016872A1 (en) * 2003-06-11 2005-02-24 Novacea, Inc. Treatment of lung cancer with active vitamin d compounds in combination with other treatments
US20070275934A1 (en) * 2004-05-10 2007-11-29 Curd John G Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US20070142339A1 (en) * 2004-05-10 2007-06-21 Novacea, Inc. Prevention of arterial restenosis with active vitamin d compounds
WO2006074226A2 (en) * 2005-01-05 2006-07-13 Novacea, Inc. Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof

Also Published As

Publication number Publication date
MXPA06013029A (es) 2007-02-12
WO2005110435A1 (en) 2005-11-24
EP1750728A4 (en) 2009-04-29
KR20070038460A (ko) 2007-04-10
JP2007537263A (ja) 2007-12-20
CA2566346A1 (en) 2005-11-24
US20070148205A1 (en) 2007-06-28
CN1950095A (zh) 2007-04-18
AU2005244061A1 (en) 2005-11-24
EP1750728A1 (en) 2007-02-14
US20070142339A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
NO20065676L (no) Forebyggelse av arteriell restenose med aktive vitamin D forbindelser.
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
WO2005000213A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
WO2005117542A3 (en) Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
AR058126A1 (es) Antagonistas y conjugados del peptido cgrp
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
WO2005049084A3 (en) Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
NO20070597L (no) Medikamtenter for a behandle kronisk respiratorisk sykdom.
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
WO2005000212A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
WO2005002506A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites
WO2004110151A8 (en) Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
MX2023012875A (es) Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef.
WO2004012746A3 (en) New uses for inhibitors of inosine monophosphate dehydrogenase
WO2006086498A3 (en) Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
BR0015039A (pt) Método para administrar um inibidor fosfodiesterase 4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application